Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hester Biosciences has informed that Board of Directors, in their Meeting held today, have approved, Unaudited Standalone Financial Results for the quarter and half year ended on 30 September, 2018, declared 2nd interim dividend of 20% that is INR 2.00 per equity share on the face value of INR 10 per share. The company has already paid 1st Interim Dividend of INR 2.00 per equity shares, and revision in remuneration of Rajiv Gandhi, CEO & Managing Director of the Company for the current tenure ending on 31 March 2020, subject to approval of Members.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: